Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microbix BiosystemsMBXBF 56 3-1 Month Momentum % is 18.81% as of Aug. 04, 2026. GuruFocus rates MBXBF with a GF Score™ of 56/100 and a GF Value™ of $0.19 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,393 Biotechnology companies, Microbix Biosystems ranks better than 81.62% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-04), Microbix Biosystems's 3-1 Month Momentum % is 18.81%.
The industry rank for Microbix Biosystems's 3-1 Month Momentum % or its related term are showing as below:
MBXBF's 3-1 Month Momentum % is ranked better than 81.62% of 1393
companies
in the Biotechnology industry
Industry Median: -6.97
vs MBXBF: 18.81
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Microbix Biosystems 3-1 Month Momentum % Related Terms
MBXBF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Microbix Biosystems's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbix Biosystems 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Microbix Biosystems's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Microbix Biosystems's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbix Biosystems (MBXBF) has a 3-1 Month Momentum % of 18.81% as of Aug. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Microbix Biosystems and its competitors. According to the industry distribution chart, Microbix Biosystems ranks #256 out of 1393 companies in the Biotechnology industry, placing it in the top 18.4%.
Is Microbix Biosystems' 3-1 Month Momentum % too high?
Microbix Biosystems' current 3-1 Month Momentum % is 18.81%. Based on the distribution chart, Microbix Biosystems ranks #256 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Microbix Biosystems has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #256 out of 1393 companies for 3-1 Month Momentum %. This places Microbix Biosystems in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current 3-1 Month Momentum % is 18.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.19, compared to a current price of $0.22 — trading 15.8% above its estimated fair value. The current 3-1 Month Momentum % is 18.81%. Microbix Biosystems' overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current 3-1 Month Momentum % is 18.81% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbix Biosystems (MBXBF) Overvalued in 2026?
Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued.
The current stock price of $0.22 is trading 15.8% above its estimated GF Value™ of $0.19.
GuruFocus considers Microbix Biosystems to be Modestly Overvalued.
Key valuation signals for MBXBF:
3-1 Month Momentum %: 18.81%
GF Value™: $0.19 vs. price of $0.22 (15.8% above fair value)
No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
56GF Score
Get the complete analysis for MBXBF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBXBF has been successfully added to your 
